Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. <i>Curr. Oncol.</i> 2023, <i>30</i>, 6097-6110.
- DOI
- 10.3390/curroncol31110529
- Published
- 2024-11-15
- Container
- Curr Oncol
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/curroncol31110529,
title = {Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. <i>Curr. Oncol.</i> 2023, <i>30</i>, 6097-6110.},
author = {Alvarado-Miranda A and Lara-Medina FU and Muñoz-Montaño WR and Zinser-Sierra JW and Galeana PAC and Garza CV and Sanchez Benitez D and Limón Rodríguez JA and Arce Salinas CH and Guijosa A and Arrieta O.},
year = {2024},
journal = {Curr Oncol},
doi = {10.3390/curroncol31110529},
url = {https://doi.org/10.3390/curroncol31110529}
}RIS
TY - JOUR TI - Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. <i>Curr. Oncol.</i> 2023, <i>30</i>, 6097-6110. AU - Alvarado-Miranda A AU - Lara-Medina FU AU - Muñoz-Montaño WR AU - Zinser-Sierra JW AU - Galeana PAC AU - Garza CV AU - Sanchez Benitez D AU - Limón Rodríguez JA AU - Arce Salinas CH AU - Guijosa A AU - Arrieta O. PY - 2024 JO - Curr Oncol DO - 10.3390/curroncol31110529 UR - https://doi.org/10.3390/curroncol31110529 ER -
APA
A, A., FU, L., WR, M., JW, Z., PAC, G., CV, G., D, S. B., JA, L. R., CH, A. S., A, G., & O., A. (2024). Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. <i>Curr. Oncol.</i> 2023, <i>30</i>, 6097-6110.. Curr Oncol. https://doi.org/10.3390/curroncol31110529
Source records
- europe-pmc · retrieved 2026-09-26T08:54:41.823Z
- doaj · retrieved 2026-09-26T08:54:41.794Z